Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Pulmonary embolism in patients with Covid-19 pneumonia

Florian Bompard, Hippolyte Monnier, Ines Saab, Mickael Tordjman, Hendy Abdoul, Laure Fournier, Olivier Sanchez, Christine Lorut, Guillaume Chassagnon, Marie-pierre Revel
European Respiratory Journal 2020; DOI: 10.1183/13993003.01365-2020
Florian Bompard
1Department of Radiology, Cochin Hospital, AP-HP.Centre, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hippolyte Monnier
2Department of Radiology, Hôpital Européen Georges-Pompidou, AP-HP.Centre, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ines Saab
1Department of Radiology, Cochin Hospital, AP-HP.Centre, Paris, France
6Université de Paris, Descartes-Paris 5, , Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mickael Tordjman
1Department of Radiology, Cochin Hospital, AP-HP.Centre, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hendy Abdoul
3Unité de Recherche Clinique Centre d'Investigation Clinique, Paris Descartes Necker/Cochin, Hôpital Tarnier, Paris, Franc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laure Fournier
2Department of Radiology, Hôpital Européen Georges-Pompidou, AP-HP.Centre, Paris, France
6Université de Paris, Descartes-Paris 5, , Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Sanchez
4Department of pulmonology and Intensive Care, Hôpital Européen Georges-Pompidou, AP-HP.Centre, Paris, France
6Université de Paris, Descartes-Paris 5, , Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Lorut
5Department of pulmonology Cochin Hospital, AP-HP.Centre, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guillaume Chassagnon
1Department of Radiology, Cochin Hospital, AP-HP.Centre, Paris, France
6Université de Paris, Descartes-Paris 5, , Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie-pierre Revel
1Department of Radiology, Cochin Hospital, AP-HP.Centre, Paris, France
6Université de Paris, Descartes-Paris 5, , Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marie-pierre Revel
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

We report an overall 24%(95% CI; 17–32%) cumulative incidence of pulmonary embolism in patients with COVID-19 pneumonia, 50% (30–70%) in ICU and 18% (12–27%) in other patients

To the editor

Acute respiratory distress syndrome developing in patients with COVID-19 pneumonia is associated with a high mortality rate and is the main cause of death in patients with SRAS-Cov-2 infection [1]. Myocardial injury has also been reported to be significantly associated with fatal outcome, with 37% mortality rate for patients without prior cardiovascular disease but elevated troponin levels [2]. Regarding other biomarkers of severity, a D-dimer level greater than 1 μg/mL has been clearly identified as a risk factor for poor outcome in SARS-Cov-2 infection [3], with recent reports highlighting a high incidence of thrombotic events in intensive care unit (ICU) patients [4]. A normal D-dimer level allows excluding safely pulmonary embolism in outpatients with low or intermediate clinical probability of pulmonary embolism (PE) but there is no recommendation to use D-dimer as a positive marker of thrombosis because of lack of specificity. An advice paper from the European Society of Radiology and the European Society of Thoracic imaging suggested that contrast-enhanced CT should be performed to rule out PE if supplementary oxygen is needed in COVID-19 pneumonia patients with limited disease extension [5]. The European Society of Cardiology also recommends CTPA before leaving the radiology department when unenhanced CT findings cannot explain the severity of respiratory failure [6]. Indeed, it is not recommended to base PE diagnosis on pulmonary ventilation-perfusion imaging [7]. The cumulative incidence of VTE on the wards is reported to be lower than in the ICU (10% versus 48% at 14 days, respectively) [8] where investigation for PE is not always feasible due to critical illness and prone position [9].

We conducted a retrospective study evaluating all CT pulmonary angiographies (CTPA) performed between March 1rst and April 16th, 2020 in patients with COVID-19 pneumonia at in two hospitals of Université de Paris (Cochin and Pompidou hospitals). The study was approved by the ethics committee of Cochin Hospital (CLEP Decision N°: AAA-2020-08009). The reason why patients had been referred for CTPA was obtained from the electronic medical records, as well as the number of days of hospitalisation at time of CT examination, the categorisation as ICU or ward patient and need for mechanical ventilation. Information regarding D-dimer level within 24 h of the CT examination was also obtained, together the modalities of prophylactic anticoagulation in hospitalised patients. CT acquisitions had been performed on multidetector CT units (SOMATOM Definition Edge or SOMATOM Definition AS, both Siemens Healthineers, Erlangen, Germany) using standard CTPA protocols. Images were analysed by 2 experienced radiologists who evaluated COVID-19 disease extent, presence or absence of intraluminal filling defects in the proximal or distal (segmental or subsegmental) pulmonary arteries and signs of acute right ventricular dysfunction.

During the study period, a total of 137 patients with confirmed SARS-Cov-2 infection and COVID-19 pneumonia underwent contrast-enhanced CT examination. All but two CT examination with major respiratory motion artifacts were of diagnostic quality, as assessed by the two expert readers. Thus, 135 patients (94 men, 70%) with a median age of 64 years [interquartile range (IQR) : 54–76 years] were included. Sixty-three of them (47%) were outpatients seen at the emergency department. They were referred for CTPA at initial presentation, because of hesitation between COVID-19 pneumonia and pulmonary embolism, after clinical probability assessment and D-dimer dosage, applying the same cutoff as for non- COVID patients. The remaining 72 patients (53%) were already hospitalised for a median of 5 days [IQR : 4–8 days] and had presented clinical respiratory deterioration, with an increase of oxygen needs. Twenty-four patients were in ICU under mechanical ventilation.

There was no disagreement between the two expert readers as well as between initial and expert reading regarding the presence of PE. A total of 32 PE were identified resulting in a 24% (95% CI; 17–32%) overall cumulative incidence, 50% (30–70%) in ICU and 18% (12–27%) in other patients. Fifteen PE were diagnosed in outpatients at initial presentation whereas the remaining 17 were diagnosed in patients who had presented clinical deterioration during hospitalisation. All inpatients received prophylactic anticoagulation (enoxaparin 40 mg once daily in ward patients, or twice daily in obese and ICU patients according to local practice). There were ten proximal PE whereas eighteen involved segmental pulmonary arteries and the remaining four PE multiple sub segmental pulmonary arteries. On CTPA there were signs of acute right ventricular dysfunction (right-to-left ventricular diameter ratio >1) in six patients, four with proximal PE including one saddle PE, and two others with segmental PE, one patient having moderate and the other severe disease extent on CT.

Comparison between the PE positive and PE negative groups of patients is summarised in the table 1. No statistical difference between groups was noted regarding age or gender.

View this table:
  • View inline
  • View popup
TABLE 1

Interestingly, disease extent on CT pulmonary angiography was not significantly different between patients with or without PE. Conversely, among the 53 patients referred for clinical respiratory deterioration who had a previous CT, increase of disease extent was more frequently observed in the PE negative group. Patients with PE were more frequently hospitalised in ICU and more frequently under mechanical ventilation, with longer median hospitalisation duration (15 [9–17] versus 8 [4–12] days, p=0.04). Regarding the outcome, there were 4 deaths in the PE positive group (4/32, 13%) and twelve in the PE negative group (12/135, 12%) within a median follow-up of 26 [22–29] and 27 [20–32] days, respectively.

D-dimer level was significantly higher in the PE group; meaning that D-dimer increase is not only a marker of pneumonia severity but is associated with a higher risk of PE. Our data do not allow defining an accurate threshold for PE risk in this specific population. However the high cumulative incidence of PE we observed suggests to more frequently use contrast medium for the evaluation of COVID-19 patients on CT.

Some authors suggested using low molecular weight heparin anticoagulant therapy in patients with severe pneumonia who have excessive activation of coagulation, defined as D-Dimer values 4-times higher than the normal upper limit [10]. Tang et al. reported lower 28-day mortality in patients with D-dimer>6 fold of upper limit of normal who received heparin at a prophylactic dose, as compared with those who did not [11].

In our study, prophylactic anticoagulation did not avoid the occurrence of PE in hospitalised patients, highlighting the need to adapt thrombosis prophylaxis in patients with SARS-Cov-2 infection.

Pulmonary embolism and deep venous thrombosis (DVT) have been reported to occur in other viral pneumonias, but not as frequently as in COVID-19 patients. Of 119 individuals admitted to the hospital with H1N1 Influenza A virus infection, seven (5.9%) experienced thrombotic vascular events, including 1 PE and three DVT [12].

Our study presents several limitations. Since contrast administration was not systematically used, our study does not allow assessing the incidence of PE for all COVID-19 patients. Whereas all patients referred because of clinical deterioration had contrast-enhanced CT, the reason why PE was suspected as concurrent diagnosis of COVID-19 pneumonia at initial presentation cannot be precisely assessed, in view of the retrospective design of our study. For the same reason, an in-depth analysis of comorbidities and especially history of venous thromboembolism was not possible. We were not able to evaluate the presence of deep venous thrombosis in our study population since none of the patients underwent compression ultrasound. . Lastly, our study does not allow defining which cutoff value of D-dimer should trigger contrast administration, when evaluating COVID-19 patients on CT. This remains an open question to be solved by a prospective evaluation.

In conclusion, we observed that almost a quarter of the COVID-19 pneumonia patients evaluated after contrast administration had acute pulmonary embolism on CT. This suggests more largely using contrast when performing thoracic CT examination in patients with COVID-19 pneumonia, especially for those with marked elevation of D-dimer.

Footnotes

  • Conflict of interest: Dr. BOMPARD has nothing to disclose.

  • Conflict of interest: Dr. MONNIER has nothing to disclose.

  • Conflict of interest: Dr. SAAB has nothing to disclose.

  • Conflict of interest: Dr. TORDJMAN has nothing to disclose.

  • Conflict of interest: Dr. ABDOUL has nothing to disclose.

  • Conflict of interest: Dr. FOURNIER reports personal fees from GENERAL ELECTRIC, non-financial support from GUERBET, personal fees from JANSSEN, from NOVARTIS, outside the submitted work;.

  • Conflict of interest: Dr. SANCHEZ reports personal fees and non-financial support from BTG, grants and personal fees from BOSTON SCIENTIFIC, grants, personal fees and non-financial support from BAYER, grants, personal fees and non-financial support from BMS, personal fees from SANOFI AVENTIS, grants from DAIICHI SANKYO, during the conduct of the study; grants, personal fees and non-financial support from MSD, grants from BOEHRINGER INGELHEIM, outside the submitted work;.

  • Conflict of interest: Dr. LORUT reports non-financial support from Covidien AG, non-financial support from NOVATECH SA, non-financial support from PROXILIO, outside the submitted work;.

  • Conflict of interest: Dr. CHASSAGNON has nothing to disclose.

  • Conflict of interest: Dr. REVEL reports personal fees from MSD FRANCE, non-financial support from GUERBET, outside the submitted work;.

  • Received April 23, 2020.
  • Accepted April 29, 2020.
  • Copyright ©ERS 2020
http://creativecommons.org/licenses/by-nc/4.0/

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Wu C,
    2. Chen X,
    3. Cai Y, et al.
    Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020.
  2. ↵
    1. Guo T,
    2. Fan Y,
    3. Chen M, et al.
    Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020.
  3. ↵
    1. Tang N,
    2. Li D,
    3. Wang X, et al.
    Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18: 844–847. doi:10.1111/jth.14768
    OpenUrlCrossRefPubMed
  4. ↵
    1. Klok FA,
    2. Kruip MJHA,
    3. van der Meer NJM, et al.
    Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020: S0049-3848(20)30120-1. [cited 2020 Apr 23]; www.linkinghub.elsevier.com/retrieve/pii/S0049384820301201.
  5. ↵
    1. Revel M-P,
    2. Parkar AP,
    3. Prosch H, et al.
    COVID-19 patients and the radiology department - advice from the European Society of Radiology (ESR) and the European Society of Thoracic Imaging (ESTI). Eur Radiol 2020.
  6. ↵
    ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic [Internet]. [cited 2020 Apr 27].Available from: www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance, www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance.
  7. ↵
    1. Zhai Z,
    2. Li C,
    3. Chen Y, et al.
    Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines. Thromb Haemost 2020.
  8. ↵
    1. Middeldorp S,
    2. Coppens M,
    3. van Haaps TF, et al.
    Incidence of Venous Thromboembolism in Hospitalized Patients with COVID-19. 2020. [cited 2020 Apr 23]; www.preprints.org/manuscript/202004.0345/v1.
  9. ↵
    1. Bikdeli B,
    2. Madhavan MV,
    3. Jimenez D, et al.
    COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. J Am Coll Cardiol 2020: S0735-1097(20)35008-7.
  10. ↵
    1. Lin L,
    2. Lu L,
    3. Cao W, et al.
    Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect 2020; 9: 727–732. doi:10.1080/22221751.2020.1746199
    OpenUrlPubMed
  11. ↵
    1. Tang N,
    2. Bai H,
    3. Chen X, et al.
    Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; 18: 1094–1099. doi:10.1111/jth.14817
    OpenUrl
  12. ↵
    1. Bunce PE,
    2. High SM,
    3. Nadjafi M, et al.
    Pandemic H1N1 influenza infection and vascular thrombosis. Clin Infect Dis 2011; 52: e14–e17. doi:10.1093/cid/ciq125
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
View this article with LENS
Vol 61 Issue 1 Table of Contents
European Respiratory Journal: 61 (1)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pulmonary embolism in patients with Covid-19 pneumonia
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Pulmonary embolism in patients with Covid-19 pneumonia
Florian Bompard, Hippolyte Monnier, Ines Saab, Mickael Tordjman, Hendy Abdoul, Laure Fournier, Olivier Sanchez, Christine Lorut, Guillaume Chassagnon, Marie-pierre Revel
European Respiratory Journal Jan 2020, 2001365; DOI: 10.1183/13993003.01365-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Pulmonary embolism in patients with Covid-19 pneumonia
Florian Bompard, Hippolyte Monnier, Ines Saab, Mickael Tordjman, Hendy Abdoul, Laure Fournier, Olivier Sanchez, Christine Lorut, Guillaume Chassagnon, Marie-pierre Revel
European Respiratory Journal Jan 2020, 2001365; DOI: 10.1183/13993003.01365-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Respiratory management of drowning associated acute respiratory failure: A multicenter retrospective cohort study
  • The impact of depression and anxiety on the risk of exacerbation in adults with bronchiectasis: A prospective cohort study
  • SNPs identified by GWAS affecting asthma risk
Show more Research letter

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society